

Cytiva acquires Canadian company Vanrx Pharmsystems

02 February 2021 | News | By BioSpectrum Bureau

The Vanrx portfolio complements Cytiva's manufacturing capacity solutions



Cytiva has acquired Vanrx Pharmsystems, a Canadian company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed to patients.

This is the first acquisition by Cytiva. Emmanuel Ligner, President and CEO, Cytiva, says: "Since becoming a Danaher operating company in April 2020, we have already begun fuelling innovation and re-investing in the business for the benefit of our customers and their patients. We are thrilled to welcome the Vanrx associates to our family and look forward to working together on delivering meaningful solutions for biomanufacturers."

The Vanrx portfolio complements Cytiva's manufacturing capacity solutions. Whereas great progress has until now focused on drug substances, this innovation is focused on drug product, which is a critical last step before distribution to patients.

Olivier Loeillot, Vice President and Head of BioProcess, Cytiva, says, "Cytiva becomes the first 'idea to injection' biotechnology company by bringing Vanrx into our already strong portfolio. From drug development, through drug substance and now into drug product, we can help biomanufacturers bring their therapies to patients faster. Vanrx will enhance Cytiva FlexFactory platforms and KUBio modular facilities, enabling us to accelerate biomanufacturing from start to finish."

Vanrx's flagship products are the SA25 Aseptic Filling Workcell and Microcell Vial Filler, which automate aseptic filling using robotics within closed, gloveless isolators. These standardised, flexible systems provide a fast and certain path to filling capacity as the final step in manufacturing clinical and commercial biopharmaceuticals. The company counts leading biopharmaceutical companies as its customers.

Chris Procyshyn, Co-founder and CEO, Vanrx, says: "We created Vanrx to enable every company to manufacture safe and cost-effective injectable therapies. Our own experience told us that new technologies are needed to support next-generation therapies and personalised medicine."